Cas:1101120-37-9 Pyrazolo[1,5-a]pyridin-5-amine manufacturer & supplier

Chemical Name:Pyrazolo[1,5-a]pyridin-5-amine

CAS.NO:1101120-37-9

Synonyms:Pyrazolo[1,5-a]pyridin-5-amine

Molecular Formula:C₇H₇N₃

Molecular Weight:133.151

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.3±0.1 g/cm3

Index of Refraction:1.697

PSA:43.32000

Exact Mass:133.063995

LogP:0.40

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Pyrazolo[1,5-a]pyridin-5-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Pyrazolo[1,5-a]pyridin-5-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyrazolo[1,5-a]pyridin-5-amine Use and application,Pyrazolo[1,5-a]pyridin-5-amine technical grade,usp/ep/jp grade.

Related News: Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors. Pyrazolo[1,5-a]pyridin-5-amine manufacturer ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States. Pyrazolo[1,5-a]pyridin-5-amine supplier The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. Pyrazolo[1,5-a]pyridin-5-amine vendor From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity. Pyrazolo[1,5-a]pyridin-5-amine factory From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity.